What this means
Researchers gave mice two compounds, alone and together, after a stroke-like injury to the brain. The mice given both had less brain damage and better nerve function than those given either one alone.
Plain-English summary written by an AI model from the abstract. The original is below.
- Who it was tested in
- Male mice
- Kind of research
- Research in animals or cells
The science
- Original title
- Elamipretide (SS-31) and Nicotinamide Mononucleotide (NMN) Combination Therapy Targets TREM2 to Mitigate Post-ischemic Brain Injury in Mice.
- Authors
- Yang Q, Zhang Y, Liu P et al.
- Journal
- Neurochemical research
- Published
- Jul 13, 2026
- Study type
- Lab or animal study · indexed as animal research
- PMID
- 42443448 ↗
Abstract
Ischemic stroke is a severe cerebrovascular disorder characterized by a cascade of pathological processes, including neuroinflammation and apoptosis. These processes lead to high mortality rates and long-term disabilities, imposing substantial socioeconomic burdens. Although reperfusion therapies have improved patient outcomes, many remain ineligible due to narrow therapeutic windows or clinical contraindications. Consequently, developing novel neuroprotective strategies is of significant clinical importance. Elamipretide (SS-31) and nicotinamide mononucleotide (NMN) are well-documented neuroprotective agents operating through distinct mechanisms; however, their combined efficacy and underlying mechanisms in ischemic stroke remain elusive. This study investigated the neuroprotective efficacy of SS-31 and NMN, alone or in combination, in a mouse model of ischemic stroke, with a specific focus on their modulation of triggering receptor expressed on myeloid cells 2 (TREM2)-mediated neuroinflammatory and apoptotic pathways. A middle cerebral artery occlusion/reperfusion (MCAO/R) model was established in male mice, followed by treatment with SS-31, NMN, or their combination. Therapeutic outcomes were evaluated using neurobehavioral scoring, histopathological staining, transcriptomic sequencing, and protein expression analyses. TREM2 overexpression experiments and specific pharmacological inhibition of the NF-κB pathway were conducted to elucidate the specific molecular mechanisms. Co-administration of SS-31 and NMN significantly attenuated post-ischemic brain damage and ameliorated neurological deficits (P < 0.0001), demonstrating effects markedly superior to either monotherapy. Transcriptomic profiling revealed that the combination therapy specifically modulated innate immune and apoptotic pathways, concomitant with a significant downregulation of TREM2. Mechanistically, the combination therapy effectively inhibited NF-κB (p65) activation, thereby downregulating TREM2 expression. This suppression attenuated microglial activation, reduced the expression of canonical pro-inflammatory cytokines (IL-1β, TNF-α, and IL-6), and rebalanced the Bcl-2/Bax apoptotic axis. Overexpression of TREM2 entirely reversed these neuroprotective benefits. Combination therapy with SS-31 and NMN provides robust neuroprotection against ischemic stroke by suppressing the NF-κB/TREM2 signaling axis, thereby combinatorially modulating post-stroke neuroinflammation and apoptosis. These findings highlight a novel, multi-targeted strategy for precision stroke interventions.
Yang Q, Zhang Y, Liu P et al. Elamipretide (SS-31) and Nicotinamide Mononucleotide (NMN) Combination Therapy Targets TREM2 to Mitigate Post-ischemic Brain Injury in Mice. Neurochemical research. 2026. doi:10.1007/s11064-026-04846-z. PMID: 42443448. https://pubmed.ncbi.nlm.nih.gov/42443448/
Related research
The Role of Oxidative Stress in Heart Failure: Mechanisms and Therapeutic Targets.
Heart failure is characterised by increased production of reactive oxygen species (ROS), which contribute to apoptotic signalling.
A peptide eased signs of aging in heart cells damaged by a cancer drug
Researchers treated heart muscle cells in a dish with a cancer drug, then a peptide called SS-31. The peptide reduced several signs of aging, but not cell cycle arrest. This was done only in lab cells, so it does not show the peptide would help people.
Peptide SS-31 eased radiation-caused aging signs in heart cells
Researchers exposed heart cells to radiation and gave some of them SS-31. SS-31 reduced several aging signs, but this was only tested in cells, not people.
Targeting Mitochondria for Postoperative Cognitive Dysfunction: From Mechanisms to Therapeutics.
Postoperative cognitive dysfunction (POCD) is a frequent neurological complication in older surgical patients, leading to substantial declines in quality of life and placing a considerable burden on society.
Two mitochondria-targeted drugs studied in aged female mice with fatty liver disease
Researchers gave two drugs to older mice with fatty liver disease caused by a rich diet. Both drugs improved liver markers in the mice, but this does not show they would help people.
The Oxidative-Mitochondrial-Inflammatory Axis in Retinitis Pigmentosa: Extracellular mtDNA as Biomarker and Therapeutic Read-Out.
Retinitis pigmentosa (RP) is the most common inherited retinal dystrophy (prevalence ~1:4000) and a leading Mendelian cause of working-age blindness.
See all research on NMN (nicotinamide mononucleotide) →